194656-75-2
194656-75-2
Chemical Structure
ABH hydrochloride
- CAS No.: 194656-75-2
- Formula:C6H15BClNO4
- Molecular Weight:211.45
IUPAC Name: (S)-2-amino-6-boronohexanoic acid hydrochloride
InChIKey: XCUVEZUCSHVMRK-JEDNCBNOSA-N
SMILES: O=C([C@H](CCCCB(O)O)N)O.[H]Cl
Biological Activity: ABH (hydrochloride) is an orally active arginase inhibitor (Ki = 8.5 nM). ABH hydrochloride promotes NO production and reduces the expression of inflammatory response-related molecules (ICAM-1, VCAM-1, MCP-1). ABH hydrochloride improves erectile function, reduces lung damage, promotes wound healing, reduces arterial blood pressure, and improves vascular fibrosis[1][2][3][4][5][6][7][8][9][10][11].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
ABH hydrochloride | 99.90% | ABH (hydrochloride) is an orally active arginase inhibitor (Ki = 8.5 nM). ABH hydrochloride promotes NO production and reduces the expression of inflammatory response-related molecules (ICAM-1, VCAM-1, MCP-1). ABH hydrochloride improves erectile function, reduces lung damage, promotes wound healing, reduces arterial blood pressure, and improves vascular fibrosis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
ABH | ABH is an orally active arginase inhibitor (Ki = 8.5 nM). ABH promotes NO production and reduces the expression of inflammatory response-related molecules (ICAM-1, VCAM-1, MCP-1). ABH improves erectile function, reduces lung damage, promotes wound healing, reduces arterial blood pressure, and improves vascular fibrosis. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Lysine-13C6 dihydrochloride | 99.83% | L-Lysine-13C6 (dihydrochloride) is the 13C-labeled L-Lysine dihydrochloride. L-lysine dihydrochloride is an essential amino acid with important roles in connective tissues and carnitine synthesis, energy production, growth in children, and maintenance of immune functions. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Lysine hydrochloride (Standard) | ≥98% | L-Lysine hydrochloride (Standard) is the analytical standard of L-Lysine hydrochloride. This product is intended for research and analytical applications. L-lysine hydrochloride is an essential amino acid for humans with various benefits including treating herpes, increasing calcium absorption, reducing diabetes-related illnesses and improving gut health. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Lysine-15N2 hydrochloride | 98.0% | L-Lysine-15N2 (hydrochloride) is the 15N-labeled L-Lysine hydrochloride. L-lysine hydrochloride is an essential amino acid for humans with various benefits including treating herpes, increasing calcium absorption, reducing diabetes-related illnesses and improving gut health. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Lysine-13C dihydrochloride | 99.90% | L-Lysine-13C (dihydrochloride) is the 13C-labeled L-Lysine dihydrochloride. L-lysine dihydrochloride is an essential amino acid for humans with various benefits including treating herpes, increasing calcium absorption, reducing diabetes-related illnesses and improving gut health. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Lysine-13C6,15N2 hydrochloride | 99.93% | L-Lysine-13C6,15N2 (hydrochloride) is the 13C- and 15N-labeled L-Lysine hydrochloride. L-lysine hydrochloride is an essential amino acid for humans with various benefits including treating herpes, increasing calcium absorption, reducing diabetes-related illnesses and improving gut health. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Lysine-13C6 hydrochloride | 98.0% | L-Lysine-13C6 hydrochloride is the 13C labeled L-Lysine hydrochloride. L-lysine hydrochloride is an essential amino acid for humans with various benefits including treating herpes, increasing calcium absorption, reducing diabetes-related illnesses and improving gut health. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Lysine6-13C dihydrochloride | L-Lysine6-13C (dihydrochloride) is a 13C-labeled L-Lysine dihydrochloride. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
DL-Lysine Monohydrochloride | 97.0% | DL-Lysine Monohydrochloride is a lysine derivative. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
D-Lysine monohydrochloride (Standard) | ≥98% | D-Lysine monohydrochloride (Standard) is the analytical standard of D-Lysine monohydrochloride (HY-Y1804). This product is intended for research and analytical applications. D-Lysine monohydrochloride is the D-enantiomer of L-Lysine (HY-N0469). D-Lysine monohydrochloride is metabolically inert and not utilized for protein synthesis by mammalian ribosomes. D-Lysine monohydrochloride blocks renal uptake of 111In/90Y-Octreotide (HY-P0036)-based probes without inhibiting uptake by tumor/receptor tissues, and thus acts as a renoprotective agent in diagnostic imaging and peptide receptor radionuclide therapy (PRRT). D-Lysine monohydrochloride specifically inhibits the early steps of non-enzymatic glycation by competing with glucose via its free amino group, theoretically, it can serve as a glycation competitor that "does not interfere with protein synthesis" under chronic hyperglycemia in diabetes. D-Lysine monohydrochloride can be used in research related to cancer and diabetes. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Vadon-Legoff S, et al. Improved and high yield synthesis of the potent arginase inhibitor: 2 (S)-amino-6-boronohexanoic acid. Organic process research & development, 2005, 9(5): 677-679
- [2]. Wang L, et al. Arginase inhibition enhances angiogenesis in endothelial cells exposed to hypoxia. Microvasc Res. 2015 Mar;98:1-8. [Content Brief]
- [3]. Tsai P, et al. Effect of the mammalian arginase inhibitor 2(S)-amino-6-boronohexanoic acid on Bacillus anthracis arginase. Curr Microbiol. 2012 Apr;64(4):379-84. [Content Brief]
- [4]. Segal R, et al. Chronic oral administration of the arginase inhibitor 2(S)-amino-6-boronohexanoic acid (ABH) improves erectile function in aged rats. J Androl. 2012 Nov-Dec;33(6):1169-75. [Content Brief]
- [5]. Kavalukas SL, et al. Arginase inhibition promotes wound healing in mice. Surgery. 2012 Feb;151(2):287-95. [Content Brief]
- [6]. Cho JS, et al. The effects of arginase inhibitor on lung oxidative stress and inflammation caused by pneumoperitoneum in rats. BMC Anesthesiol. 2015 Sep 28;15:129. [Content Brief]
- [7]. Yao L, et al. Obesity-induced vascular inflammation involves elevated arginase activity. Am J Physiol Regul Integr Comp Physiol. 2017 Nov 1;313(5):R560-R571. [Content Brief]
- [8]. Mehl A, et al. Effect of arginase inhibition on pulmonary L-arginine metabolism in murine Pseudomonas pneumonia. PLoS One. 2014 Mar 3;9(3):e90232. [Content Brief]
- [9]. Krause BJ, et al. Chronic Intermittent Hypoxia-Induced Vascular Dysfunction in Rats is Reverted by N-Acetylcysteine Supplementation and Arginase Inhibition. Front Physiol. 2018 Jul 24;9:901. [Content Brief]
- [10]. Bhatta A. Involvement of arginase upregulation in diabetes-and angiotensin II-induced vascular dysfunction. 2015.
- [11]. Toso A, et al. Congenital diaphragmatic hernia: phosphodiesterase-5 and Arginase inhibitors prevent pulmonary vascular hypoplasia in rat lungs. Pediatr Res. 2024 Mar;95(4):941-948. [Content Brief]
